Immagino tu avessi già acquistato, anche perché ormai il treno è passato
Immagino tu avessi già acquistato, anche perché ormai il treno è passato
Comunque come conio pare sia parecchio sottovalutato e ora si sta svegliando
Poi magari domani vale 10 euro e bon, chi lo sa
Credo abbia anche a che fare con PancakeSwap
Ultima modifica di ZioYuri78; 19-02-21 alle 17:01
Ubisoft è scesa del 20% in 2 mesi, secondo voi prenderla per fare un 10% nel giro di un paio di mesi può essere una buona idea?
Mmh, io oggi nel dip pescato Apple per custodirla a lungo e un po' di Palantir anche se mi sa che con questa me la prendo in culo perché va di moda ma è tardi. Per farci solo il 10% io neanche mi sbatterei.
AAPL è un must.
Ricordo ancora che avevo acquistato 10000€ di azioni più di 10 anni fa, quando ancora si doveva andare in banca allo sportello per farlo.
Le ho rivendute dopo circa un anno contento del 70% di guadagno. Venduto pure li allo sportello, dopo telefonata preventiva, con la ricevuta stampata dalla stampante ad aghi e la tizia scioccata per la plusvalenza
Ovviamente le avessi tenute fino ad adesso ci avrei fatto il 1000%, ma allora non immaginavo che stonks only go up
tornando a immunome, dehor cosa ne pensi?
Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, announced today that its discovery engine has isolated potent antibodies capable of neutralizing several SARS-CoV-2 variants, including the South African Variant (B.1.351), in pseudovirus testing.
This effort is part of the company’s ongoing program to develop a cocktail of antibodies targeting spike and non-spike proteins that can serve as a prophylaxis or a treatment for COVID-19. Immunome’s COVID-19 antibody research demonstrates that SARS-CoV-2 “super-responders” who recover from SARS-CoV-2 mount a robust immune response to a broad range of viral targets, including spike and non-spike proteins (https://www.biorxiv.org/content/10.1...01.27.428534v1).
As part of developing our antibody cocktail (IMM-BCP-001), Immunome has identified antibodies that bind to non-overlapping regions of the spike protein, including those regions containing the critical mutational variants. Immunome’s research shows that certain of our antibodies neutralize pseudoviruses expressing the spike protein of the South African Variant (B.1.351). Recent literature suggests that this South African Variant reduces the effectiveness of certain vaccines and antibody therapies (https://www.biorxiv.org/content/10.1...01.25.427948v1, https://www.biorxiv.org/content/10.1...01.25.428137v2).
Purnanand Sarma, PhD, CEO of Immunome, said, “Our findings underscore the power of Immunome’s discovery engine to quickly identify antibodies that are broadly effective against SARS-CoV-2 and its variants. Of note, Immunome’s discovery engine has identified antibodies that bind to conserved epitopes of SARS-CoV-1 and SARS-CoV-2 spike, as well as to other non-spike targets. We believe that our comprehensive strategy could combat the negative impact of escape mutants. We are encouraged by these results and plan to continue development efforts on these antibodies.”
Jeffrey P Henderson, MD, PhD, Associate Professor of Medicine and of Molecular Microbiology at Washington University School of Medicine in St. Louis, and a member of Immunome’s COVID-19 Advisory Board, said, “Interrogating the overall immune responses in recovered COVID-19 patients allows Immunome to identify not only broadly neutralizing anti-spike antibodies but also promising non-spike antibodies that have the potential to enhance viral clearance. Broadly targeting multiple viral proteins in this way may provide alternative approaches to combat future SARS-CoV-2 variants.”
In July 2020, Immunome was awarded a $13.3 million technology award from the U.S. Department of Defense's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), in collaboration with the Defense Health Agency, to support Immunome’s COVID program. The research discussed in this press release and the article is part of that program.
Immunome is a biopharmaceutical company that utilizes its proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics that are designed to change the way diseases are treated. The company’s initial focus is on developing therapeutics to treat oncology and infectious diseases, including COVID-19. Immunome’s proprietary discovery engine identifies novel therapeutic antibodies and their targets by leveraging the highly educated components of the immune system, memory B cells, from patients whose bodies have learned to fight off their disease. For more information, please visit www.immunome.com.
This press release and the article referenced within includes certain disclosures that contain “forward-looking statements” intended to qualify for the “safe harbor” from liability established by the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding Immunome’s beliefs and expectations regarding the advancement of its oncology and COVID-19 therapeutic antibody programs, execution of its clinical and strategic plans, anticipated upcoming milestones for IMM-BCP-01 and IMM‐ONC‐01, including expectations regarding therapeutic potential and benefits thereof, and IND filings. Forward-looking statements may be identified by the words “anticipate,” believe,” “estimate,” “expect,” “intend,” “plan,” “project,” “may,” “will,” “could,” “should,” “seek” and similar expressions. Forward-looking statements are based on Immunome’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, those risks and uncertainties associated with: the impact of the COVID-19 pandemic on Immunome’s business, operations, strategy, goals and anticipated milestones, Immunome’s ability to execute on its strategy including with respect to the timing of its R&D efforts, IND filings, initiation of clinical studies and other anticipated milestones, the timing and effectiveness of any antibody therapeutics which may be developed by Immunome, Immunome’s ability to fund operations and the additional risks and uncertainties set forth more fully under the caption “Risk Factors” in Immunome’s final prospectus dated October 1, 2020 and filed pursuant to Rule 424(b) under the Securities Act of 1933, as amended, with the United States Securities and Exchange Commission (SEC) and elsewhere in Immunome’s filings and reports with the SEC. Forward-looking statements contained in this announcement are made as of this date, and Immunome undertakes no duty to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable law.
Secondo me quando ne parlano su reddit ed esce qualche notizia è già troppo tardi. Questa cosa era da sapere prima e aver comprato prima, e adesso che tutti comprano vendi.
Beh sapere prima della notizia non è possibile a meno che non conosci chi ci lavora dentro le aziende
La parola d'ordine è HOLD
Immunome crollata a 38 e comparsa oggi su un intesa. Cd projekt ancora no...chi ha Fineco mi può dire se ha thq nordic/embracer group che mi interessa?
se non sono quotate non le potete acquistare tramite mercati regolamentati
Corsair iCue5000X RGB - Asus ROG-STRIX Z690 F-GAMING ARGB - Intel Core i7 12700K - Corsair iCue H150i Capellix RGB - 2X Corsair Dominator Platinum RGB DDR5 5600MHz 16GB - Samsung 980PRO M.2 1TB NVMe PCIe - PCS 1TBe SSD M.2 - Seagate Barracuda 2TB - Corsair 1000W RMx Series MOD. 80PLUS GOLD - Asus ROX-STRIX GEFORCE RTX3070Ti 8GB - Kit 4 ventole Corsair LL120 RGB LED - Windows 11 64bit
Embracer che sarebbe Thq nordic non è regolamentata? https://www.google.com/search?q=thq+...obile&ie=UTF-8
Ultima modifica di Biocane; 20-02-21 alle 21:15
bio cane quante volte devo scrivertelo
Thq nordic/embracer è OTC (Over the counter), non puoi acquistarla con un fottuto broker italiano
Project coso lo trovi o OTC o sulla borsa polacca, quindi non puoi acquistarla con un broker italiano
Sega e Capcom giapponesi, idem
Ultima modifica di Dehor; 21-02-21 alle 13:56